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ABSTRACT
Birthweight and risk of Autoimmune and Thyroid Conditions Within the Women’s
Health Initiative
MAY 2021
BRIAN C. MONAHAN, B.S, UNIVERSITY OF MAINE
M.S, UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Cassandra Spracklen
Autoimmune and thyroid conditions account for a substantial proportion of the morbidity
and mortality experienced in the United States, affecting >40 million Americans combined. Cooccurrence of both an autoimmune and thyroid condition is also likely, particularly among
women. Epidemiologic studies on both sets of conditions have examined many risk factors,
including demographic, lifestyle, genetic, and environmental risk factors. However, one area
which has been neglected is the effect of early life exposures on the development of autoimmune
and thyroid conditions. To investigate the potential association between an individual’s birth
weight (by category; <6lbs, 6-7lbs 15 oz, 8-9 lbs 15oz, ≥10lbs) and risk for autoimmune and
thyroid conditions, we performed a nested case-control study among 76,087 multiethnic
postpartum women in the Women’s Health Initiative (WHI) Observational cohort. Logistic
regression models were used to estimate crude and adjusted odds ratios for associations between
birth weight and: (1) autoimmune conditions (rheumatoid arthritis (RA), systemic lupus
erythematosus (lupus), multiple sclerosis, type 1 diabetes, and ulcerative colitis/Crohn’s disease),
and (2) thyroid conditions (hypothyroidism, hyperthyroidism, and goiter). After adjustments,
birth weight was positively associated with odds for any thyroid condition (combined; P<0.02)
and negatively associated with odds for hyperthyroidism (P=0.0002) within our prevalent model.
Further, birth weight was significantly associated with hypothyroidism (P=0.0009) such that
women weighing <6 lbs, 8-9.9 lbs, or ≥10lbs were at increased odds for hypothyroidism. No
significant associations were observed between birth weight and any of the autoimmune
conditions or goiter. Lupus (HR 1.51 [1.12, 2.03]) in all models and Hypothyroidism with the
unadjusted model (HR 1.18 [1.05,1.31] were also demonstrated to be at increased risk within the
incident analysis. RA and Hypothyroidism produced no significant results within the Incident
analysis. Our results further support the Developmental Origins of Health and Disease Hypothesis
postulating that diseases that occur in childhood and later in life result from environmental
exposures in utero and early childhood, extending the hypothesis to include thyroid conditions.
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CHAPTER 1:
INTRODUCTION

1.1 Overview
Autoimmune conditions pose a significant health risk around the world. It is
estimated that there are 14.7 million people living with an autoimmune condition in the
US1. The prevalence of autoimmune disease is on the rise from 9 million people in 19972
to 14.7 million people in 20121. Common autoimmune conditions include type 1 diabetes
(T1D), systemic lupus erythematosus (SLE), multiple sclerosis (MS), rheumatic arthritis
(RA), ulcerative colitis (UC), and Crohn’s disease (CD).
Thyroid conditions have a burden similar in scale to autoimmune conditions.
Currently there are an estimated 20 million Americans living with a thyroid condition.
Thyroid conditions are classified into 4 main categories: underactive thyroid
(hypothyroidism), overactive thyroid (hyperthyroidism), goiter, and thyroid nodules. The
most common causes of thyroid conditions are cancers, autoimmune thyroid diseases
(AITDs) such as Hashimoto’s thyroiditis and Graves’ disease, and iodine deficiencies.
While not all thyroid conditions are autoimmune in nature, a bulk of autoimmune thyroid
conditions are underdiagnosed as it is often easier to just manage the symptoms then
diagnose the condition3,4.
Co-occurrence of both an autoimmune and thyroid condition is also likely,
particularly among women5–7. It is estimated that 5-10% of RA patients and 17-30% of
T1D patients will suffer from some sort of thyroid condition 8,9. Further, thyroid, and
autoimmune conditions share many common risk factors, including smoking, body mass
index (BMI), age, ethnicity, and presence of an immune condition. By in large, however
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,the most consistent and major risk factors for autoimmune and thyroid conditions are
family history and sex5,10–12: Women bear most of the burden of both autoimmune and
thyroid disease.

1.2 Epidemiology: Autoimmune Conditions
The immune system controls the body’s ability to eradicate and control infections
from other pathogenic organisms, as well as assist in the repair process of other organ
systems. The immune system functions through a variety of cell types and proteins that
are made to recognize foreign invaders. Autoimmune conditions can result from the mis
regulation and/or mistargeting of the immune system which results in immune system
recognizing the body as a foreign invader13. As a group, each of the conditions are
classified by autoantibody activity, or the presence of immune receptors that target one’s
own body 13–15. These autoantibodies can affect different parts of the body, such as the
pancreas (T1D) 16, joints (RA) 17, neurons (MS) 18, gastrointestinal system (UC/CD) 19, or
just general cell surface receptors that are ubiquitous throughout the body (lupus) 20.
While some autoimmune conditions, such as T1D, have very clear clinical presentation
many others manifest with non-descript symptoms4. For example, RA shares a lot of
similar clinical symptoms with Osteoarthritis often leading to the underdiagnoses of
Rheumatoid arthritis.

1.2.1 Lupus
Lupus is an autoimmune condition which targets a wide variety of body systems
causing widespread inflammation and tissue damage in the joints, skin, lungs, kidneys,
blood vessels, and brain 21–24. According to the Lupus Foundation of America, 1.5 million
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Americans are estimated to be living with some form of lupus, 23 90% of which are
women. Individuals are typically diagnosed with SLE between the ages of 15-44 and
experience a variety of symptoms, such as skin rashes, fevers, joint pain/swelling, and
fatigue 23. Persons afflicted with lupus are known to experience periods of “flare ups”,
during which the individual may experience more severe symptoms or new symptoms
that they may not have previously had 20,21,25. Flare ups can happen at any time, but are
especially likely when a person with lupus is experiencing higher levels of emotional,
mental, or physical stress 20.
Lupus can be deadly if left untreated. Early death as a result lupus is usually due
to complications caused by infections, while death later in life is typically associated with
atherosclerosis, or the buildup of fats on large to medium sized arterial walls 26. The
increased risk for atherosclerosis in lupus patients has been demonstrated to be associated
with high disease activity, treatments for the disease and other markers such as
antiphospholipid antibodies27. Treatments for lupus focus on managing symptoms and
can vary widely based on the individual 20. Common treatments can include non-steroidal
anti-inflammatory drugs (NSAIDs), antimalarials, corticosteroids, immunosuppressants,
and monoclonal antibodies.
There are several known risk factors for the development of lupus. The most
prevalent risk factor is sex: women are six times more likely to develop lupus than men
28

. Additional prominent risk factors include minority racial and ethnic groups, age (15-

44 years), and family history 28. Further, genome-wide association studies (GWAS) have
identified >120 regions of the genome (“loci”) to be associated with an individual’s risk
for lupus29.
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1.2.2 Multiple Sclerosis
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system
30–32

. MS is characterized by an exaggerated immune response to myelin, the compound

that coats and insulates the neuron fibers 30, resulting in communication problems
between the brain and the rest of the body. Advanced stages of MS can even lead to
permanent nerve damage, such as degradation of the axon itself 30,31. It is estimated that
2.3 million people, globally, are living with MS. Diagnoses usually occur between 20-50
years of age with women bearing most of the burden of disease. Common symptoms of
MS include: fatigue, vision problems, numbness, muscle spasm, mobility problems, and
cognitive issues with thinking and mental health. 30,31.
MS is a progressive disease meaning it will continue to worsen over the course of
the person’s life 18,33.. Relapses, pr periods of intense symptoms, usually occur rapidly,
reaching a plateau that can last weeks until they subside 18,33. Relapsing-remitting MS
(RRMS) is the least severe and causes the least amount of complications. Within 15 years
of the initial diagnosis, RRMS can develop into secondary progressive MS (SPMS),
which is more severe. SPMS is characterized by its neurodegenerative complications:
cognitive impairment and increasing severity of common MS symptoms 18,33. The final
form of MS is primary progressive MS (PPMS), which is characterized by a faster
progression, more localized disease etiology, and more severe complications/symptoms,
such as paraparesis and cognitive and progressive visual failure 33. While treatments for
MS are broad and specific to the individual 18,30,33, there are two major strategies used:
disease modifying treatments that reconstitute or suppress the immune system, and
symptom-managing treatments 18.
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Risk factors for MS are similar to those of other autoimmune conditions 2,31. Age,
female sex, geographical region, and racial or ethnic background are the most wellknown and well-established risk factors 32. Specifically, women bear most of the burden
of disease (74% of cases) 31, and individuals of northern European-ancestry are diagnosed
more frequently than those of other ancestries. There is also a positive association
between MS and distance from the equator where those who live further from the equator
have a higher risk for disease 18,30. Over 230 genetic variants have also demonstrated
significant association with the risk for MS 34.

1.2.3 Rheumatoid Arthritis
Rheumatoid Arthritis (RA) is a common autoimmune condition characterized by
inflammation of the lining of the joints that can eventually result in bone erosion and/or
joint deformity 35–37. In some individuals, RA can also damage the skin, eyes, lungs,
heart, and blood vessels. RA is one of the most characterized autoimmune conditions,
estimated to afflict 1.36 million people in the US with diagnoses starting as early as 30
years of age.
RA causes a variety of symptoms including tender or swollen joints, stiffness,
fatigue, fever, and even loss of appetite 36. As mentioned above, RA does not have to
affect only the joints but has been shown to cause complications with other body systems.
These complications can range from minor effects such as mouth dryness to more serious
inflammation of the cardiovascular system35–37. The hallmark treatment for rheumatoid
arthritis is the use of disease modifying antirheumatic drugs (DMARDs). Drugs included
in the treatment of RA include: hydroxychloroquine, methotrexate, sulfasalazine,
leflunomide, minocycline, azathioprine, cyclosporine, gold, cyclophosphamide,
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antirheumatic biologic agents (i.e., tumor necrosis factor-α and interleukin 1 antagonists)
17,38–40

.

Because RA is one of the more common autoimmune conditions 17,36,41, quite a bit
is known about its epidemiology. Common risk factors for RA include age, smoking,
higher BMI, and family history/genetic predisposition 37. There is also a large sex
disparity: 75% of individuals diagnosed with RA are women 41. However, both fish and
moderate alcohol consumption have been demonstrated to protect against RA
development and symptom expression 37.

1.2.4 Type 1 Diabetes
Type 1 diabetes (T1D) is a chronic autoimmune condition in which the pancreas
produces little to no insulin as a result of destruction or dysfunction of pancreatic beta
cells 42,43. T1D has a global incidence of about 15 per 100,000 people. Within the US, the
incidence is higher at 20 per 100,000 persons with a prevalence of 12.2 per 100,000
people. Unlike other autoimmune conditions, there is no difference in disease prevalence
between sexes 43,44; however, there is a significant difference in mortality 45 with women
being at a 40% greater risk of death.
There are several broad, moderate symptoms associated with T1D, ranging from
frequent urination to extreme fatigue 46,47. However, there are several severe and/or lifethreatening complications that can arise from mistreatment or lack of treatment, including
diabetic ketoacidosis, neuropathy, glaucoma, cataracts, and various cardiovascular
diseases such as high blood pressure and strokes 46,47. The most unique complication is
diabetic ketoacidosis, which occurs when blood sugar levels are high, and ketones begin
to build up within the blood stream. The primary treatment for T1D is insulin injection 47.
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The other treatments include lifestyle changes, such as diet, blood sugar monitoring, and
physical activity.
With the exact cause of T1D unknown, little is also known about the risk factors
for T1D. Individuals with a family history of T1D are an increased risk for developing
the disease; in fact, genetic studies have identified 80 loci associated with T1D48, further
illustrating the genetic nature of the condition. Other suggested risk factors for T1D
include: white race 43,49; adolescent age 49, puberty; and environmental stressors such as
entero-infections during pregnancy, Vitamin D deficiency, and intestinal microbiota50.
Unlike type 2 diabetes, diet and lifestyle habits are not associated with risk for T1D.

1.2.5 Ulcerative colitis/ Crohn’s disease
Ulcerative colitis (UC) and Crohn’s disease (CD) are autoimmune conditions of
the gastrointestinal tract 19,51–53. While the two conditions are very similar in presentation
and epidemiology, UC is continuous inflammation of the inner most layer of the colon
whereas CD can occur anywhere along the digestive tract (from mouth to anus) with both
inflamed and healthy tissues mixed together 19,51. Around 214 people out of 100,000
persons per year in the United states will be diagnosed with UC with CD being more rare
at 3.1-20.2 per 100,000 individuals per year51,53. Unlike many of the other autoimmune
conditions previously mentioned, there is no sex discrepancy in prevalence rates of UC or
CD 51,53.
Symptoms of both UC and CD include persistent and often bloody diarrhea,
abdominal cramps/pain, and bowel urgency 19. While the conditions are limited to the
gastrointestinal tract, complications of both conditions can affect a person’s overall health
such as fevers, weight loss, low energy/fatigue, loss of appetite, anemia, and delayed
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growth or development in children 51. There are many different treatments for UC/CD.
According to The Chron’s and Colitis foundation, there are 30 FDA approved drugs
across 5 classes 54,55. The medications as well as dietary changes are the main treatments
for UC/CD. In some instances, an individual may undergo surgery to remove a heavily
affected portion of the bowel, and the remaining ends are joined together 53.
The exact causes of UC and CD are unknown; however, both are much more
common in individuals with a family history of either condition. Previously, diet and
stress were suspected risk factors; research has now shown these factors may aggravate
the condition and cause flare-ups but are not responsible for disease etiology 19,52. It is
now believed that UC and CD are triggered by a malfunction in the immune system of
those with a genetic susceptibility or predisposition for UC/CD 19. It has been suggested
that an abnormal immune response to an invading virus or bacterium my cause the
immune system to attack cells in the digestive tract as well, leading to UC/CD. In fact,
there is a known association with the presence of Clostridium difficile and flare ups of
both UC and CD. Nonetheless, the cause of the malfunctioning immune system or
abnormal immune response is still to be determined 51,52.

1.3 Epidemiology: Thyroid Conditions
The thyroid is a small, butterfly-shaped endocrine gland that sits along the front of
the windpipe. It has two lobes that are connected by the isthmus in the middle56,57. The
thyroid is primarily responsible for secreting two thyroid hormones—triiodothyronine
(T3) and thyroxine (T4)—and a peptide hormone called calcitonin. T3 and T4 are
responsible for maintaining the metabolic rate, cardiovascular function, sexual function,
sleep patterns, and protein synthesis, as well as growth and development in children56,57.
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Calcitonin plays a role in calcium homeostasis. Thyroid hormone production in the
thyroid is regulated by thyroid-stimulating hormone (TSH) released by the anterior
pituitary gland. Clinically significant conditions of the thyroid include functional
disorders58,59 (hyper- and hypothyroidism), as well as several diseases (e.g., nodules60,
goiter61, Graves’ disease62, Hashimoto’s thyroiditis63, thyroid cancer64). While not all
thyroid conditions are autoimmune diseases, many have autoimmune etiologies. One of
the leading causes of hyper- and hypothyroidism is Graves’ Disease and Hashimoto’s
thyroiditis, respectively 6,58,65, both of which are autoimmune conditions. Goiter
etiologies also include Graves’ disease and Hashimoto’s thyroiditis 3.

1.3.1 Hyperthyroidism
Overactive thyroid, or hyperthyroidism, occurs when the thyroid gland produces
too much T4, resulting in unintentional weight loss from an accelerated metabolism and a
rapid and/or irregular heartbeat 58,62,66. In the US it is estimated that 1-3% of the
population is living with overt hyperthyroidism 67. It can be caused by a number of
conditions, including thyroiditis, thyroid nodules and Graves’ disease 62,68. Other
symptoms of hyperthyroidism include: heart palpitations, fatigue, tremors, anxiety, heat
intolerance, and disturbed sleep 58. Treatment for hyperthyroidism is highly dependent on
the cause of hyperthyroidism 69–72. Medication against thyroid hormone production,
radioactive iodine, and surgery are among the most common treatments for
hyperthyroidism.
There are several known risk factors for hyperthyroidism. Women are affected
more frequently than men 58,65. with an average onset between 40-60 years of age 58,65.
Individuals are also at higher risk if they are of white race or of Japanese ancestry,
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consume a diet high in saltwater fish and/or iodine, have an autoimmune condition, or
have a family history of hyperthyroidism or Graves’ disease 58,69,73.

1.3.2 Hypothyroidism
An underactive thyroid, or hypothyroidism, is a condition in which the thyroid
gland does not produce enough thyroid hormone 59. Hypothyroidism is among the more
common conditions of the thyroid in western countries with between 3-7% of the US
population having the condition 59. Hypothyroidism may be a result of a number of
factors, including: Hashimoto’s thyroiditis or other autoimmune disease 63,74, overresponse to hyperthyroidism treatment, thyroid surgery, radiation therapy, medications, a
pituitary disorder, or an iodine deficiency. Cold and dry skin, brittle nails, bradycardia,
delayed reactions, ataxia, fatigue, and elevated blood pressure are all common symptoms
of an underactive thyroid 59,63. Untreated hypothyroidism can lead to several health
problems, such as goiter, heart problems, mental health issues, neuropathies, myxedema,
infertility, and birth defects 59. The primary treatment for hypothyroidism is
levothyroxine, a synthetic form of thyroid stimulating hormone (TSH).
Epidemiological studies of hypothyroidism have identified several common risk
factors for disease development. Like hyperthyroidism, women are more likely to
develop hypothyroidism than men. Additional risk factors include: >60 years of age,
family history of thyroid disease, presence of an autoimmune condition, history of
treatment with radioactive iodine or anti-thyroid medications, history of radiation to the
neck or upper chest, thyroid surgery, and having been pregnant or delivered a baby within
the last six months 59.
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1.3.3 Goiter
Goiter, or the enlargement of the thyroid, can be broken up into two main groups:
diffuse and nodular goiter. While iodine deficiency is the most common cause of goiter
worldwide 3, chronic autoimmune diseases, such as Hashimto’s thyroiditis and Graves’
disease are the most common causes of goiter within the US 60,61. In the US it is estimated
that 4.7% of the population is living with some form of goiter61.
The symptoms of goiter can vary due to the different types and causes of the
goiter. Goiters come in two forms toxic and non-toxic 3,60,71. Toxic goiter is characterized
by increasing size of the thyroid partnered with the over production of the thyroid
hormone thyroxine. Toxic goiter shares similar symptomology with hyperthyroidism,
and, if left unchecked, can result in additional physical symptoms such as airway
obstruction due to the large size of thyroid. Treatment options for toxic goiter typically
include radioiodine therapy, antithyroid medication, and/or surgery71. Non-toxic goiter
are only characterized by increasing thyroid size but is not accompanied by
hyperthyroidism 60. Non-toxic goiter can also be treated with radioiodine therapy,
antithyroid medication, and/or surgery71 unless it is accompanied by hypothyroidism, in
which case levothyroxine can be used in place of antithyroid medication 60.
Because goiters have multiple etiologies, complications vary based on the cause
of the disease 60,713,63,72. However, there is on complication that is ubiquitous across goiter
types: increased risk for thyroid cancer. Studies have shown that 10-20% of persons with
a goiter will develop thyroid cancer 75. Further, if the goiter is allowed to grow in size,
upper airway obstructions may become problematic and require surgical removal of the
goiter.
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Goiter does not have many independent risk factors. The most well researched
risk factors for developing goiter are iodine deficiency61, and autoimmune conditions,
such as Hashimoto’s thyroiditis or Graves Disease3,76.

1.4 Birthweight and the risk for autoimmune and thyroid conditions
The Developmental Origins of Health and Disease Hypothesis (DOHD), (also
known as the “fetal origins hypothesis” or the “Barker Hypothesis”) is a hypothesis that
postulates that chronic disorders or conditions in later life can result from environmental
factors in utero (e.g., fetal malnutrition) and early childhood that permanently “program”
the structure and function of systems within the body 77. The hypothesis, outlined by
David Barker in “Fetal and Infant Origins of Adult Disease” (1992) 78 has demonstrated
an individual’s birth weight as a risk factor for many chronic diseases in both children
and adults, such as autism79, attention deficit/hyperactivity disorder80, cardiovascular
disease 81, type 2 diabetes82, cancer83, and later-life disability 84.
There is also evidence that prenatal factors, such as an individual’s birth weight,
may influence the development of the immune system. Children born at low and high
birth weights are at substantially increased risk for asthma85. Further, children born at
higher birth weights are at increased risk for allergic diseases, including eczema, food
allergies, hay fever, and anaphylaxis86. Although alterations of the immune system can
persist into adulthood, the relationship of the DOHD and immune conditions remains
elusive for select conditions. There are several conditions with limited or conflicting
evidence while others like T1D are thoroughly examined.
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1.5 Physiological Connection
Fetal insults in utero, including maternal and fetal exposures that result in infants
born at both low (<2500 g) and high (≥ 4500 g) birth weights, have been shown to illicit
epigenetic modifications of genes throughout the genome87. These epigenetic
mechanisms, which orchestrate fetal growth and development, may also remain
“programmed” throughout an individual’s life, putting them at risk for later health
consequences. In fact, several studies have demonstrated significant differences in
patterns of DNA methylation by birth weight that have persisted past infancy88–90. Further
investigation is warranted to determine which epigenetic modification(s) may be most
influential to the development of autoimmune and thyroid conditions.
Apart from epigenetic modifications, there is some evidence that birth weight may
influence the development of the immune system. Infants born following intrauterine
growth restriction (IUGR) have been found to have a global downregulation of the
immune system, often associated with allergic disorders within children 82. Infants born
IUGR and with low birth weights (<2500 grams) have also demonstrated a transient shift
in T-cell and cytokine balance, altering systemic inflammatory responses91,92.
Additionally, low birth weight has been associated with low grade inflammation as well
as several innate immune cells such as overall leukocytes, basophils, eosinophils and
even platelets after adjusting for family history 93, and both inflammation and overactive
immune responses are known to be risk factors for autoimmune conditions.

1.6 Study Objectives, Significance, and Innovation
This study proposes to assess the relationship between an individual’s weight at
birth and risk for autoimmune (RA, MS, T1D, lupus, and UC/CD) and thyroid
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(hypothyroidism, hyperthyroidism, and goiter) conditions. Specifically, the aims of the
study are:
Aim 1: To assess the relationship between birth weight and the risk of
autoimmune conditions such as rheumatoid arthritis, lupus, multiple sclerosis, ulcerative
colitis, Crohn’s disease, and type 1 diabetes.
Hypothesis 1: We postulate that infants born at lower weights (< 6lbs) will be at
an increased risk of developing autoimmune conditions overall.
Aim 2: To assess the relationship between birth weight and the risk of thyroid
conditions such as hyperthyroidism, hypothyroidism, and goiter.
Hypothesis 2: We postulate that infants born at lower weights (< 6 lbs.) will be at
an increased risk of developing thyroid conditions overall.
Because many autoimmune conditions are known to also affect the thyroid, it is
common for individuals to have at least one autoimmune condition and a thyroid
condition. This co-occurrence suggests a natural combination of the two sets of
phenotypes. Studies relating birth weight to autoimmune and thyroid conditions are
sparse and most have been conflicting. This study would be among the first to look at a
large range of autoimmune and thyroid conditions within the same population rather than
examine individual conditions in different populations. Further, the sample size and
prospective design of the Women’s Health Initiative allows to analyze both prevalent and
incident outcomes.
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CHAPTER 2
METHODS

2.1 Women’s Health Initiative
The Women’s Health Initiative (WHI) is an ongoing prospective cohort study
designed to study major causes of chronic disease in postmenopausal women. Briefly,
161,608 post-menopausal women aged 50-79 at enrollment were recruited from the
general population at 40 US clinical recruitment sites between 1993-1998 94. Participants
could have enrolled into overlapping clinical trials (WHI-CT; n = 67,932) or the longterm observational study (WHI-OS; n = 93,676). Detailed information about the WHI’s
study design, recruitment, and implementation have been described elsewhere 94,95. All
study protocols were approved by the Institutional Review Board of each participating
clinical center, and all participants provided written informed consent at study initiation.

2.2 Baseline Measures
Upon entry into the WHI-OS, all women completed structured, self-administered
questionnaires to collect information on demographics; lifestyle factors; and medical,
reproductive, and family history. Participants were asked to report their birth weight as
one of the following categories: less than 6 pounds (lbs), 6 lbs to 7lbs 15ounces, 8 lbs to
9lbs 15 oz, and 10 or more lbs. The collection of birth weight is comparable to other
studies of similar size and has been previously validated within those studies 96. Women
were also asked to report if they were born 4 or more weeks premature or were part of a
multiple pregnancy (specifically, a twin or triplet). Further, a physical assessment was
performed by trained staff to gather accurate measures of weight, height, and waist and

15

hip circumference at baseline. Participants were also asked to bring all current
medications with them to the physical assessment.

2.3 Follow-up for outcome ascertainment
Clinical outcomes, including incident autoimmune and thyroid condition
diagnoses, were reported by participants annually through in-person, mailed, and/or
telephone questionnaires. In the third year of follow-up, women were invited to a followup clinical visit for an updated physical assessment. Like the assessment performed at
baseline, the follow-up clinical visit was performed to gather updated anthropometric
measures, as well as an updated list of current medications and other outcome
information.

2.4 Outcome definitions and measurement
Data on prevalent thyroid and autoimmune conditions were obtained at baseline
through the self-administered questionnaires. Women were first asked to report if a
doctor had ever told them that they had a thyroid problem (yes/no/don’t know). If they
answered yes, they were then asked a series of sub-questions (yes/no/don’t know) about
specific thyroid conditions. We included the following thyroid conditions in our analyses:
any thyroid gland problem, overactive thyroid, underactive thyroid, and goiter.
We included the following prevalent autoimmune conditions in our analyses: any
autoimmune disease, type 1 diabetes (T1D), multiple sclerosis (MS), rheumatoid arthritis
(RA), lupus (lupus), and Crohn’s disease/ulcerative colitis (CD/UC). We defined
prevalent MS, lupus, and CD/UC as a self-report of a physician diagnosis of “multiple
sclerosis”, “systemic erythematosus (‘lupus’ or SLE)”, or “ulcerative colitis or Crohn’s
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disease”, respectively. Due to the lack of a specific variable for distinguishing those with
type 1 and type 2 diabetes, we classified women has having T1D if they meet the
following criteria reported at baseline: 1) self-reported physician diagnosis of ‘sugar
diabetes when not pregnant; 2) reported the age of diabetes diagnosis < 30; and 3)
reported using insulin as a treatment for their diabetes. Additionally, as the self-reported
variable for RA has been poorly validated within WHI and often includes cases of
osteoarthritis as shown in a previous study 38, we classified women as having prevalent
RA if they simultaneously met the following criteria:1) self-reported type of arthritis as
“rheumatoid arthritis” ; and 2) use of disease-modifying antirheumatic drugs (DMARDs).
Incident data were available for several of the thyroid and autoimmune
conditions. Beginning in the third year of follow-up, women were asked to self-report
any new lupus, RA, underactive thyroid, and/or overactive thyroid diagnoses that had
occurred since the last completed survey. Women were considered as incident cases for
each outcome if they responded “yes” to a recent diagnosis of lupus, underactive, and/or
overactive thyroid. Like prevalent RA, women were required to indicate a recent
diagnosis of RA and use DMARDs to be classified as an incident case of RA. Because
medication coding only occurred in the third year of follow-up, our incident RA analyses
were censored at the third year of follow-up.

2.5 Study Exclusion Criteria
For our analyses, women were excluded if they reported being born premature
(n=7,282), reported being a twin or a triplet (n=1,616), or had a missing birth weight
category (n=11,751). Women who had previously been diagnosed with a particular
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condition prior to enrollment were excluded from the survival analyses for that same
condition.

2.6 Statistical Analyses
Baseline characteristics of the study participants with and without any
autoimmune or thyroid condition were examined using t-tests for continuous variables
and chi-square tests for categorical variables. Logistic regression models were used to
estimate odds ratios (OR) and their associated 95% confidence intervals (95% CI)
between a woman’s birth weight and prevalent cases of autoimmune (any, RA, MS,
lupus, T1D, and UC/CD) or thyroid (any, underactive, overactive, goiter) conditions with
and without adjusting for potential risk factors. Cox proportional hazards regression
models were used to estimate hazard ratios (HR) and 95% CI between a woman’s birth
weight and incident cases of lupus, RA, underactive thyroid, and overactive thyroid with
and without adjusting for potential risk factors. For birth weight, we used “6 lbs. to 7 lbs.
15 oz” as the referent category as infants born full-term within this weight range are
considered to be of normal birth weight. Covariates selected for inclusion in our models
are well-known risk factors for most autoimmune and/or thyroid conditions including
age, race/ethnicity, region, BMI, smoking status, education, Normalized Socio-Economic
Status (NSES), and alcohol use. All statistical tests were two-sided, and P-values <0.05
were considered statistically significant. Each outcome was considered independently
with birth weight; therefore, we did not correct for multiple testing. For conservative
interpretation, a Bonferroni-adjusted significance threshold of P<0.0035 (0.05/14) could
be considered. All analyses were performed using SAS 9.4 (SAS Institute Inc., Cary,
NC, USA).
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CHAPTER 3:
RESULTS
Results from the comparison of baseline characteristics are outlined in Table 1.
Women with any autoimmune condition at baseline were more likely to be younger,
identify as non-white, have a lower NSES, and have a lower BMI than women who did
not report the presence of an autoimmune condition at baseline. Conversely, women who
reported having any thyroid condition at baseline were more likely to be older, identify as
white, and have a higher BMI, then women who did not report the presence of a thyroid
condition at baseline.
Table 2 shows the crude and demographic- and lifestyle-adjusted odds of thyroid
and autoimmune conditions by category of birth weight. Birth weight was significantly
and positively associated with odds for any thyroid condition (all types combined) at
baseline (unadjusted, P<0.0001). The association remained significant after adjustment
for demographic (P=0.005) and lifestyle (P=0.02) factors, although the strength of the
association was attenuated. A significant negative association was observed between
birth weight and the odds for overactive thyroid (adjusted, P=0.009). Further, birth
weight was significantly associated with underactive thyroid (adjusted, P=0.0002) such
that women weighing <6 pounds, 8-9.9 pounds or ≥10 pounds at birth were at
significantly increased odds for underactive thyroid. The magnitude of these associations
is relatively modest ranging from fully adjusted OR’s of 1.14 (CI 1.02, 1.28) in the No
significant associations were observed between birth weight and the odds for goiter, RA,
MS, lupus, T1D, CD/UC, or any autoimmune disease (all types combined).
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Crude and demographic- and lifestyle-adjusted hazards ratios of incident thyroid
and autoimmune conditions are presented in Table 3. Women born in the highest birth
weight category, >10 lbs, were at significantly increased risk for lupus in both crude (HR:
1.47, 95%CI 1.14-1.94) and adjusted models (demographic-adjusted, HR=1.43, 95% CI
1.08-1.90; demographic- and lifestyle-adjusted, HR=1.51, 95% CI 1.12-2.03) compared
to women born weighting between 6 lbs – 7 lbs 15 oz. Women born weighing >10 lbs
were also at significantly increased risk for underactive thyroid compared to women
weighing 6 lbs – 7 lbs 15 oz at birth (unadjusted, HR=1.18, 95% CI 1.05-1.31); however,
this association was attenuated after adjustments for covariates. No significant
associations were detected within the incident models for overactive thyroid or RA.
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414 (45.5)
426 (46.8)
70 (7.7)

338 (22.8)
699 (49.8)
370 (27.3)
74.9 (9.1)
27.8 (6.3)

1175 (81.1)
134 (11.0)
29 (2.6)
54 (3.9)
24 (1.7)

63.3 (7.0)

145 (10.2)
939 (66.2)
278 (19.6)
57 (4.02)

3,727 (10.9)
17,928 (52.3)
12,625 (36.8)

16,884 (49.7)
15,073 (44.3)
2,039 (6.0)

7380 (22.0)
16,413 (48.7)
9,898 (29.3)
75.8 (8.5)
28.1 (6.3)

29,143 (85.8)
2,648 (8.0)
593 (1.8)
987 (3.0)
493 (1.5)

64.8 (7.1)

2,900 (8.5)
22,748 (67.0)
7,003 (20.6)
1,310 (3.9)

No
Autoimmune
(n=33,961)

116 (12.7)
572 (62.7)
225 (24.6)

Any
Autoimmune
(n=1,419)

<0.0001

0.01

<0.0001
<0.0001

0.43

0.0002

<0.0001

0.55

Pa

8,971 (47.9)
8,683 (46.4)
1,067 (5.7)

3,313 (17.6)
9,120 (48.5)
6,379 (33.9)
76.6 (7.9)
27.7 (6.0)

16,992(89.8)
916 (4.8)
303 (1.6)
432 (2.3)
272 (1.4)

64.2 (7.2)

1,580 (8.3)
12,626 (66.6)
4,068 (21.5)
684 (3.6)

6,024 (10.7)
27,794 (49.5)
22,372 (39.8)

28,551 (51.1)
23,671 (42.4)
3,618 (6.5)

11,714 (20.9)
27,156 (48.5)
17,182 (30.7)
76.1 (8.5)
27.1 (5.8)

47,276 (83.9)
4,592 (8.2)
1,534 (2.7)
2,119 (3.8)
802 (1.4)

63.0 (7.4)

4,721 (8.4)
38,632 (68.4)
11,196 (19.8)
1,926 (3.4)

No Thyroid
(n=56,475)

1,876 (10.0)
9,866 (52.3)
7,119 (37.7)

Any Thyroid
(n=18,958)

Table 1: Baseline characteristics of 81,517 WHI study participants, by autoimmune or thyroid condition status

Birth weight
<6 lbs
6-7.99 lbs
8-9.99 lbs
≥10 lbs
Age at baseline (mean, STD)
Race/Ethnicity
White
Black
Asian/Pacific islander
Hispanic
Other/Unknown
Education
<High school diploma/GED
School after high school
College degree or higher
Normalized socioeconomic status (NSES; mean, STD)
BMI at Baseline ( mean, STD)
Smoking status
Never
Past
Current
Alcohol use
Non-Drinker
past drinker/Average Drinker
Current drinker

Pb

<0.0001

<0.0001

<0.0001

<0.0001

<0.0001
<0.0001

<0.0001

<0.0001

Numbers are N (%) for categorical variables or mean (standard deviation) for continuous variables.
a
P-values are from t-tests and Chi-square statistics and compare women with "any autoimmune" condition to the women with "no autoimmune"
condition (among those used in this analysis).
b
P-values are from t-tests and Chi-square statistics and compare women with "any thyroid" condition to the women with "no thyroid" condition (among
those used in this analysis).
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Table 2 Continued
Rheumatoid
arthritis
(555=cases)
Unadjusted
(cases
555)
adj for Demographics a (cases = 548)
adj for Demographic and Lifestyle factors b (cases = 497)

1.02 [0.82,1.26]

0.99 [0.88,1.56]

1.26 [0.82,1.93]

1.19 [0.78,1.82]

1.09 [0.72,1.67]

0.76

0.81

0.71

23

1.00 [Ref]

0.98 [0.82,1.24]

111

1.17 [0.88,1.56]
1.00 [Ref]

366

1.10 [0.82,1.47]

1.00 [Ref]

55

1.03 [0.75,1.41]

1.02 [0.73,1.39]

0.87 [0.38,1.97]

0.84 [0.40,1.80]

0.93

0.89

0.89

<20
1.00 [Ref]

1.08 [0.79,1.50]

0.82 [0.34,2.01]

49

0.85 [0.51,1.40]

1.00 [Ref]

1.06 [0.75,1.50]

163

Unadjusted (cases = 236)

0.90 [0.54,1.48]

1.00 [Ref]

<20

adj for Demographics a (cases=226)

0.92 [0.54,1.57]

Multiple sclerosis (236 cases)

adj for Demographic and Lifestyle factors b (cases=195)

0.88 [0.68,1.15]

0.99 [0.57,1.16]

0.94 [0.54,1.65]

0.82

0.78

0.68

<20
1.00 [Ref]

0.89 [0.68,1.16]

1.03 [0.57,1.84]

71
1.11 [0.79,1.57]

1.00 [Ref]

0.88 [0.66,1.17]

270

Unadjusted (cases = 391)

1.08 [0.77,1.16]

1.00 [Ref]

37

adj for Demographics a (cases=388)

1.04 [0.72,1.52]

Lupus (391 cases)

adj for Demographic and Lifestyle factors b (cases=335)

N/A

0.42

0.28

<20
0.53 [0.29,1.00] *

N/A

<20*
1.00 [Ref]

0.57 [0.31,1.07] *

0.33

69
1.38 [0.73,2.61]

1.00 [Ref]

N/A

<20

Unadjusted (cases = 88)

1.32 [0.69,2.51]

0.46 [0.23,1.01] *

Type 1 diabetes (88 cases)
adj for Demographics a (cases=86)

1.13 [0.56,2.28]

1.01 [0.86,1.19]

0.97 [0.68,1.40]

0.99 [0.69,1.43]

0.57

0.55

0.71

31
1.00 [Ref]

0.98 [0.83,1.16]

0.97 [0.66,1.43]

184
1.15 [0.91,1.44]

1.00 [Ref]

1.00 [0.83,1.19]

611

Unadjusted (cases = 912)

1.17 [0.93,1.47]

1.00 [Ref]

86

1.00 [Ref]

adj for Demographic and Lifestyle factors b (cases=77)

adj for Demographics a (cases=902)

1.19 [0.93,1.52]

Ulcerative colitis (912 cases)

adj for Demographic and Lifestyle factors b (cases=782)

Lifestyle factors include smoking status, education, normalized socioeconomic status, and alochol use.

Demographic factors include age, race, region, and BMI.

* T1D higher birthweight categories combined due to too few persons in the largest category
a
b

c
Policy from the Women's Health Initiative will not allow researchers to report number of participants in cells less than 20. As such, cells that contain fewer than 20
participants read "<20".
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< 6 lbs
OR (95% CI)
9,569

590
1.05 [0.96, 1.14]

0.05
0.08
0.29

0.83
0.87
0.55

0.047
0.09
0.25

269
1.18 [1.05, 1.31]
1.11 [0.98, 1.25]
1.12 [0.98, 1.27]
90
1.06 [0.86, 1.31]
1.02 [0.83, 1.27]
1.01 [0.80, 1.26]

0.04
0.07
0.04

1,387
1.01 [0.95, 1.07]
0.98 [0.93, 1.04]
0.99 [0.93, 1.05]
469
0.92 [0.83, 1.02]
0.92 [0.83, 1.02]
0.93 [0.84, 1.04]

4,713
1.00 [Ref]
1.00 [Ref]
1.00 [Ref]
1,698
1.00 [Ref]
1.00 [Ref]
1.00 [Ref]

<20
0.46 [0.06, 3.30]
0.48 [0.07, 3.50]
0.54 [0.07, 3.91]
54
1.47 [1.14, 1.94]
1.43 [1.08, 1.90]
1.51 [1.12, 2.03]
1.00 [Ref]
1.00 [Ref]
1.00 [Ref]

47
<20
1.00 [Ref]
0.84 [0.44, 1.57]
1.00 [Ref]
0.87 [0.46, 1.64]
1.00 [Ref]
0.86 [0.44, 1.68]
740
212
0.95 [0.82, 1.11]
0.96 [0.83, 1.12]
0.97 [0.82, 1.14]

Table 3: Relationship of birth weight to Incident autoimmune and Incident thyroid conditions among women in the Women's Health Initiative.
Birth weight category
6-7.9 lbs
8-9.9 lbs
≥ 10 lbs
OR (95% CI)
OR (95% CI)
OR (95% CI)
P
53,537
15,709
2,702
81,517

Thyroid conditions
Underactive Thyroid (6,959 cases)
Unadjusted (cases = 6,959)
1.08 [0.99, 1.18]
adj for Demographicsa (cases = 6,872)
[0.96, 1.16]
adj for Demographic and Lifestyle factors b (cases = 1.05
5,975)
Overactive Thyroid (cases)
233
Unadjusted (cases = 2,490)
1.14 [1.00, 1.31]
1.13 [0.99, 1.33]
adj for Demographicsa (cases=2,464)
1.10 [0.95, 1.28]
adj for Demographic and Lifestyle factors b (cases=2,126)

<20
0.95 [0.38, 2.38]

1.04 [0.84, 1.29]
adj for Demographicsa (cases=1,080)
1.02 [0.81, 1.30]
adj for Demographic and Lifestyle factors b (cases=930)
Demographic factors include age, race, region, and BMI.

0.88 [0.35, 2.22]
adj for Demographicsa (cases = 65)
adj for Demographic and Lifestyle factors b (cases = 0.39
57) [0.09,1.61]
Lupus (1,099 cases)
93
Unadjusted (cases = 1,099)
1.05 [0.84, 1.30]

Rheumatoid arthritis (65 cases)
Unadjusted (cases = 65)

Autoimmune conditions

a

b
Lifestyle factors include smoking status, education, normalized socioeconomic status, and alochol use.
c
Policy from the Women's Health Initiative will not allow researchers to report number of participants in cells less than 20. As such, cells that
contain fewer than 20 participants read "<20".
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CHAPTER 4
DISCUSSION
In the WHI, a well-established cohort of post-menopausal women, we found that
women born within the heaviest birth weight category (>10 lbs) were at increased odds
for underactive thyroid and decreased odds for overactive thyroid compared to women
born at a normal birth weight. Further, the highest birth weight category was associated
with increased risk for incident lupus compared to the normal birth weight category.

4.1 Comparison with prior literature
To our knowledge, the body of existing literature for the associations between
birth weight and most autoimmune conditions is limited and inconsistent. Four studies
were identified that examined the association between birth weight and RA, of which one
found no association97, one found individuals born with low birth weights to be at
decreased odds for RA 98, and three studies found those born at higher birth weights to be
at increased risk for RA 96,99,100. The study design most comparable to ours was
performed within the Nurses’ Health Study (NHS)96, a large nationwide prospective
study. The analysis found an increased risk of RA at the highest birth weight category of
>4.54 kg (RR 2.1 95% CI 1.2-3.6) compared to the normal birth weight category of 3.23.85 kg. While we found no association in our study between birth weight and RA, the
NHS included a more thorough ascertainment of the RA outcome with medical chart
abstraction conducted by trained rheumatologists 96. Even after validation with drug data,
the RA variable used in the WHI study only reaches an estimated positive predictive
value of 62.2% 38.
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We also identified four studies that previously examined the association between
birth weight and lupus 101–104. Two studies found no association between birth weight and
lupus when examining birth weight by category 102 or as a continuous variable 101. One
study performed within the national cohort, NIEHS Sister Study103, identified low birth
weight (<2,500 grams) to be significantly associated with the odds for lupus (OR 2.2,
95% CI 1.2-3.9) while another study with the NHS cohort identified high birth weight (≥
10 lbs) to be associated with increased risk for lupus (RR 2.7, 95% CI 1.2-5.9) 104. The
lupus results pose an interesting dilemma. In our prevalent data analysis, there was no
significant association between lupus and any birthweight category in agreeance with 2 of
the previous studies 101,102. However, the incident data suggests a positive association
with between higher birthweights and risk for lupus, agreeing with the NHS study 104.
When we compare the outcome validation criteria for each study, our WHI study has the
least stringent criteria.
Only three studies were identified that examined the association between birth
weight and MS. Two studies found no association between birth weight and MS,
including a longitudinal study conducted in Canada and a study performed within the
NHS 105,106. Within the longitudinal Canadian study, birthweight was assessed as a
continuous variable, and no association was detected with MS, even after stratification by
sex (female P=0.48; male P=0.92). The analysis conducted within the NHS analyzed
birth weight as a categorical variable 106. An additional case control study from
Argentina found high birth weight (≥4kg) to increase the odds for MS in men (OR 6.58,
95%CI 4.81-8.99) and women (OR 4.5, 95% CI 3.06-6.58) 107. However, this study is
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greatly limited by an unreliable population selection as well as a lack of transparent
analysis, and therefore, is not internally valid.
There were two articles examining birthweight, among other early life factors,
and risk of development of UC/CD 108,109. Both studies found no association between
birth weight and incident cases of UC or CD. It is worth noting that both studies
separated CD and UC into separate outcomes, while we were unable to do so due to the
method of data collection within WHI. However, our results were consistent with these
two prior studies.
In contrast to the other autoimmune conditions, a great deal of research has been
done examining the association between birth weight and T1D. A meta-analysis110
looking at 29 studies predominantly within Europe demonstrated that children born at
both 3.5 - 4 kg (OR 1.06 95% CI 1.01-1.11) and above 4kg (OR 1.10 95% CI 1.04-1.19)
were at a higher risk for T1D. out of the studies within the meta-analysis none of the
studies focused on postmenopausal women. This result is further bolstered by several
other studies conducted more recently 111–113. Our results depart from this previously
explored relationship; however, our study had much lower power to detect an association,
highlighted by our small number of cases (n<100) divided across four birth weight
groups. this could be in large part to do with the population selected by WHI. Women
collected by WHI must live long enough to become post-menopausal. T1D is known to
become increasingly crippling as life goes on and might contribute to them being less
likely to participate in a study such as this one. Additionally, T1D was never reported as
its own variable within WHI and was collected in tandem with T2D. Due to the lack of
T1D variable, a set of criteria had to be made that could ascertain T1D from T2D. This is
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a large departure compared the other studies which used medical records from patient
registries 112,113, individual patient data 110, and hospital statistics 111. The lack of a
validated T1D variable could have resulted in improper classification cases and could
have been another reason that this study demonstrated a null result.
While the existing literature examining possible links between a person’s weight
at birth and risk for autoimmune conditions is mostly limited, literature examining the
impact of birth weight and thyroid conditions is even more scarce. We were able to locate
one study that considered the association in twin pairs discordant for overt thyroid
disease and found no associations between birth weight and autoimmune thyroid disease
(Graves’ and Hashimoto’s thyroiditis) or non-autoimmune thyroid disease (simple goiter
and toxic nodular goiter) 114. However, we found women born weighing ≥ 10 lbs were at
significantly increased odds of underactive thyroid and decreased odds for overactive
thyroid. One possibility for this discrepancy is the use of twins. Twins were one of our
exclusion criteria due to the presence of competition for resources within the gestational
environment as well as twins being born at a significantly lower weight then single birth
115

. Another possibility is our substantially larger sample size, which afforded us

sufficient power to detect the association. The discrepancy in results could be further
explained by our broad assessment of thyroid conditions that does not specifically assess
autoimmune thyroid conditions. Finally, the twin control study design of the existing
study could be susceptible to overmatching, which could bias their results towards the
null. Other studies have considered the relationship between birth weight and thyroid
cancers 64,116,117and found a ubiquitous association with increased risk at higher
birthweights.
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4.2 Strengths & Limitations
This study has several key strengths. The WHI has a large sample size with
extensive phenotype data collection at baseline. The prospective design of the WHI also
allowed us to consider incident cases for four of our outcomes with up to 8 years of
follow-up data available. We were also able to evaluate a broad spectrum of potential
confounders that may account for the underlying association between birth weight and
autoimmune or thyroid conditions.
Our study also has several limitations. First, our study was limited to evaluating
categories of birth weight based on the woman’s self-report. While the most ideal birth
data collection method would have been a quantitative measure obtained through medical
records or birth certificates, self-reported birth weight by category has been shown to
correlate well with medical record data in validity studies118,119. Further, any bias that
might result from potential misclassification of birth weight would be nondifferential.
Despite the large sample size of WHI, power remained a concern for most of the
autoimmune outcomes. As stated above, the literature has demonstrated that extremely
high birth weight is associated with increased risk for several autoimmune conditions.
However, with <20 individuals within the high birthweight category half of the examined
conditions, this relationship becomes difficult to detect with statistical significance. This
lack of power increases the likelihood of a type 2 error or the acceptance of a false null
hypothesis. The lack of power limited the secondary effect modification that would have
been useful for conditions like lupus which is known to affect persons of color more than
those of other races.
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Birthweight is not the only variable that was collected in a self-reported
categorical manner. All the outcomes along with some of the covariates were also
recorded this way. While this has not been demonstrated to be of concern for the
covariates it is a concern within some of the outcome variables. RA is one such variable
with questionable validity within WHI. In a 2008 study validating the responses of the
study in terms of secondary outcomes RA was found to be inaccurate 38. The inaccuracy
was theorized to result from confusion with osteoarthritis, which has a different etiology
then RA. To increase the validity of the RA variable, we used medication data collected
by WHI to validate if the subject was taking drugs indicative of RA 38. The validation
strategy was easy to implement for the RA baseline analysis but was more intricate when
working with the incident data. Because medication data was only taken at baseline and 3
years after enrollment, it was impossible to validate any case that occurred after this 3rd
follow-up year. Due to this secondary limitation, it was decided that the follow-up of the
incident RA cases would be artificially terminated at the time of the medication
collection on the 3rd year of follow-up. Another variable that was called into question in
the same WHI validation study was lupus. However, upon analysis of the paper there was
a much smaller group (total N=42; lupus cases=2) available for comparison, and the
validity was indeterminate 38.
Another limitation of this study is the lack of key covariates associated with these
conditions. Familial history of these diseases is one such covariate. All the conditions
have demonstrated that family history of the disease is a strong indicator for the
development of the condition13,59,67. Another variable that is key for thyroid variables is
the availability of iodine exposure data. The WHI did not collect information related to
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iodine levels or consumption within the observational study participants. Iodine
deficiency has a large effect on thyroid conditions and is the most common cause of
thyroid conditions in poorer regions of the world 59,65,72,120. However, because iodine
deficiency is thought to be a minor cause in more developed regions of the world,
including the US, we would not expect this potential confounder to have much influence
on our results.
Lastly the use of prevalent data comes with its own set of challenges and
limitations. Prevalent data often suffers from causal problems as both exposure and
outcome measured at the same point in time and therefore are usually hard to establish
that the exposure predates the outcome, and that the outcome does not predate the
exposure. For this study in particular this limitation is not of a concern as birth weight is
one of the earliest exposures available and therefore it is unlikely that outcome
supersedes our exposure of interest. The limitation of prevalent data is also circumvented
for select outcomes that were included in the incident analysis. In this instance we have
separation of exposure data collection and onset of disease and therefore can assume that
exposure superseded the disease occurrence.

4.3 Future Directions
Further research examining the associations between a person’s weight at birth
and subsequent risk for autoimmune and thyroid conditions is warranted. The existing
body of literature for all examined conditions (except for T1D) is very limited and
conflicting. While we were able to add to the body of evidence for many of the
conditions, our analyses were of limited power for detecting associations, particularly for
MS, lupus, and RA. In addition, we found significant associations between the highest
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birth weight category and under- and over-active thyroid, results that now need to be
replicated in additional populations. Further, we were unable to consider several
potentially vital confounding variables, including family history of the conditions and
iodine, nor were we able to consider potential racial disparities in the birth weight and
autoimmune or thyroid condition relationship.

32

BIBLIOGRAPHY:
1.

2.

3.

4.
5.
6.

7.

8.

9.

10.
11.

12.

13.
14.

15.
16.
17.

Hayter SM, Cook MC. Updated assessment of the prevalence, spectrum and case
definition of autoimmune disease. Autoimmun Rev. 2012;11(10):754-765.
doi:10.1016/j.autrev.2012.02.001
Jacobson DL, Gange SJ, Rose NR, Graham NMH. Epidemiology and estimated
population burden of selected autoimmune diseases in the United States. Clin
Immunol Immunopathol. 1997;84(3):223-243. doi:10.1006/clin.1997.4412
Bel Lassen P, Kyrilli A, Lytrivi M, Corvilain B. Graves’ disease, multinodular
goiter and subclinical hyperthyroidism. Ann Endocrinol (Paris). 2019;80(4):240249. doi:10.1016/j.ando.2018.09.004
McLeod DSA, Cooper DS. The incidence and prevalence of thyroid
autoimmunity. Endocrine. 2012;42(2):252-265. doi:10.1007/s12020-012-9703-2
Kahaly GJ, Hansen MP. Type 1 diabetes associated autoimmunity. Autoimmun
Rev. 2016;15(7):644-648. doi:10.1016/j.autrev.2016.02.017
Antonelli A, Ferrari SM, Corrado A, Di Domenicantonio A, Fallahi P.
Autoimmune thyroid disorders. Autoimmun Rev. 2015;14(2):174-180.
doi:10.1016/j.autrev.2014.10.016
Conigliaro P, D’Antonio A, Pinto S, et al. Autoimmune thyroid disorders and
rheumatoid arthritis: A bidirectional interplay. Autoimmun Rev.
2020;19(6):102529. doi:10.1016/j.autrev.2020.102529
Conigliaro P, D’Antonio A, Pinto S, et al. Autoimmune thyroid disorders and
rheumatoid arthritis: A bidirectional interplay. Autoimmun Rev.
2020;19(6):102529. doi:10.1016/j.autrev.2020.102529
Biondi B, Kahaly GJ, Robertson RP. Thyroid Dysfunction and Diabetes Mellitus:
Two Closely Associated Disorders. Endocr Rev. 2018;40(3):789-824.
doi:10.1210/er.2018-00163
Stojan G, Petri M. Epidemiology of systemic lupus erythematosus: An update.
Curr Opin Rheumatol. 2018;30(2):144-150. doi:10.1097/BOR.0000000000000480
Svendsen AJ, Kyvik KO, Houen G, et al. On the Origin of Rheumatoid Arthritis:
The Impact of Environment and Genes-A Population Based Twin Study. PLoS
One. 2013;8(2). doi:10.1371/journal.pone.0057304
Wang L, Wang F-S, Gershwin ME. Human autoimmune diseases: a
comprehensive update. J Intern Med. 2015;278(4):369-395.
doi:10.1111/joim.12395
Cooper GS, Stroehla BC. The epidemiology of autoimmune diseases. Autoimmun
Rev. 2003;2(3):119-125. doi:10.1016/S1568-9972(03)00006-5
Dinse GE, Parks CG, Weinberg CR, et al. Increasing Prevalence of Antinuclear
Antibodies in the United States. Arthritis Rheumatol. 2020;72(6):1026-1035.
doi:10.1002/art.41214
Gershwin LJ. Current and Newly Emerging Autoimmune Diseases. Vet Clin North
Am - Small Anim Pract. 2018;48(2):323-338. doi:10.1016/j.cvsm.2017.10.010
Gillespie KM. Type 1 diabetes: Pathogenesis and prevention. CMAJ.
2006;175(2):165-170. doi:10.1503/cmaj.060244
Scott DL, Wolfe F, Huizinga TWJ. Rheumatoid arthritis. In: The Lancet. Vol 376.
Lancet Publishing Group; 2010:1094-1108. doi:10.1016/S0140-6736(10)60826-4

33

18.
19.

20.
21.
22.

23.

24.

25.

26.

27.
28.

29.

30.
31.

32.

33.

Dobson R, Giovannoni G. Multiple sclerosis – a review. Eur J Neurol.
2019;26(1):27-40. doi:10.1111/ene.13819
Yu YR, Rodriguez JR. Clinical presentation of Crohn’s, ulcerative colitis, and
indeterminate colitis: Symptoms, extraintestinal manifestations, and disease
phenotypes. Semin Pediatr Surg. 2017;26(6):349-355.
doi:10.1053/j.sempedsurg.2017.10.003
Maidhof W, Hilas O. Lupus: An overview of the disease and management options.
P T. 2012;37(4):240-249. /pmc/articles/PMC3351863/. Accessed March 25, 2021.
Ugarte-Gil MF, González LA, Alarcón GS. Lupus: the new epidemic. Lupus.
2019;28(9):1031-1050. doi:10.1177/0961203319860907
Drenkard C, Lim SS. Update on lupus epidemiology: Advancing health disparities
research through the study of minority populations. Curr Opin Rheumatol.
2019;31(6):689-696. doi:10.1097/BOR.0000000000000646
Lupus facts and statistics | Lupus Foundation of America.
https://www.lupus.org/resources/lupus-facts-and-statistics. Accessed March 15,
2021.
Rees F, Doherty M, Grainge MJ, Lanyon P, Zhang W. The worldwide incidence
and prevalence of systemic lupus erythematosus: A systematic review of
epidemiological studies. Rheumatol (United Kingdom). 2017;56(11):1945-1961.
doi:10.1093/rheumatology/kex260
Fortuna G, Brennan MT. Systemic lupus erythematosus. Epidemiology,
pathophysiology, manifestations, and management. Dent Clin North Am.
2013;57(4):631-655. doi:10.1016/j.cden.2013.06.003
Tunnicliffe DJ, Singh-Grewal D, Kim S, Craig JC, Tong A. Diagnosis,
Monitoring, and Treatment of Systemic Lupus Erythematosus: A Systematic
Review of Clinical Practice Guidelines. Arthritis Care Res. 2015;67(10):14401452. doi:10.1002/acr.22591
Stojan G, Petri M. Atherosclerosis in systemic lupus erythematosus. J Cardiovasc
Pharmacol. 2013;62(3):255-262. doi:10.1097/FJC.0b013e31829dd857
Somers EC, Marder W, Cagnoli P, et al. Population-based incidence and
prevalence of systemic lupus erythematosus: The Michigan lupus epidemiology
and surveillance program. Arthritis Rheumatol. 2014;66(2):369-378.
doi:10.1002/art.38238
Wang YF, Zhang Y, Lin Z, et al. Identification of 38 novel loci for systemic lupus
erythematosus and genetic heterogeneity between ancestral groups. Nat Commun.
2021;12(1). doi:10.1038/s41467-021-21049-y
Howard J, Trevick S, Younger DS. Epidemiology of Multiple Sclerosis. Neurol
Clin. 2016;34(4):919-939. doi:10.1016/j.ncl.2016.06.016
Wallin MT, Culpepper WJ, Campbell JD, et al. The prevalence of MS in the
United States: A population-based estimate using health claims data. Neurology.
2019;92(10):E1029-E1040. doi:10.1212/WNL.0000000000007035
Who Gets MS? | National Multiple Sclerosis Society.
https://www.nationalmssociety.org/What-is-MS/Who-Gets-MS. Accessed March
15, 2021.
Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple
sclerosis. Lancet. 2018;391(10130):1622-1636. doi:10.1016/S0140-

34

34.

35.
36.
37.

38.

39.
40.

41.

42.

43.
44.
45.

46.

47.

48.

6736(18)30481-1
Patsopoulos NA, Baranzini SE, Santaniello A, et al. Multiple sclerosis genomic
map implicates peripheral immune cells and microglia in susceptibility. Science
(80- ). 2019;365(6460). doi:10.1126/science.aav7188
Westwood OMR, Nelson PN, Hay FC. Rheumatoid factors: what’s new?
Rheumatology. 2006;45(4):379-385. doi:10.1093/rheumatology/kei228
Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet.
2016;388(10055):2023-2038. doi:10.1016/S0140-6736(16)30173-8
Deane KD, Demoruelle MK, Kelmenson LB, Kuhn KA, Norris JM, Holers VM.
Genetic and environmental risk factors for rheumatoid arthritis. Best Pract Res
Clin Rheumatol. 2017;31(1):3-18. doi:10.1016/j.berh.2017.08.003
Walitt BT, Constantinescu F, Katz JD, et al. Validation of self-report of
rheumatoid arthritis and systemic lupus erythematosus: The Women’s Health
Initiative. J Rheumatol. 2008;35(5):811-818.
http://www.ncbi.nlm.nih.gov/pubmed/18398940. Accessed June 23, 2020.
Firestein GS, McInnes IB. Immunopathogenesis of Rheumatoid Arthritis.
Immunity. 2017;46(2):183-196. doi:10.1016/j.immuni.2017.02.006
Naqvi AA, Hassali MA, Aftab MT. Epidemiology of rheumatoid arthritis, clinical
aspects and socio-economic determinants in Pakistani patients: A systematic
review and meta-analysis. J Pak Med Assoc. 2019;69(3):389-398.
Hunter TM, Boytsov NN, Zhang · Xiang, Schroeder K, Michaud K, Araujo AB.
Prevalence of rheumatoid arthritis in the United States adult population in
healthcare claims databases, 2004-2014. Rheumatol Int. 2017;3:1551-1557.
doi:10.1007/s00296-017-3726-1
Maahs DM, West NA, Lawrence JM, Mayer-Davis EJ. Epidemiology of type 1
diabetes. Endocrinol Metab Clin North Am. 2010;39(3):481-497.
doi:10.1016/j.ecl.2010.05.011
Barnett R. Type 1 diabetes. Lancet. 2018;391(10117):195. doi:10.1016/S01406736(18)30024-2
DiMeglio LA, Evans-Molina C, Oram RA. Type 1 diabetes. Lancet.
2018;391(10138):2449-2462. doi:10.1016/S0140-6736(18)31320-5
Malik S. Gender Disparities in Mortality in Patients With Type 1 Diabetes American College of Cardiology. American College of Cardiology.
https://www.acc.org/latest-in-cardiology/articles/2015/05/18/12/17/genderdisparities-in-mortality-in-patients-with-type-1-diabetes. Published 2015.
Accessed March 25, 2021.
Jayasimhan A, Mansour KP, Slattery RM. Advances in our understanding of the
pathophysiology of Type 1 diabetes: lessons from the NOD mouse. Clin Sci
(Lond). 2014;126(1):1-18. doi:10.1042/CS20120627
Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical
interventions in type 1 diabetes. Nature. 2010;464(7293):1293-1300.
doi:10.1038/nature08933
Chiou J, Geusz RJ, Okino M-L, et al. Large-scale genetic association and single
cell accessible chromatin mapping defines cell type-specific mechanisms of type 1
diabetes risk 2 3. bioRxiv. January 2021:2021.01.13.426472.
doi:10.1101/2021.01.13.426472

35

49.

50.
51.
52.

53.

54.
55.
56.
57.
58.
59.
60.
61.

62.

63.
64.

65.

66.

67.

Maahs DM, West NA, Lawrence JM, Mayer-Davis EJ. Epidemiology of type 1
diabetes. Endocrinol Metab Clin North Am. 2010;39(3):481-497.
doi:10.1016/j.ecl.2010.05.011
Rewers M, Ludvigsson J. Environmental risk factors for type 1 diabetes. Lancet.
2016;387(10035):2340-2348. doi:10.1016/S0140-6736(16)30507-4
Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative
colitis. Lancet. 2017;389(10080):1756-1770. doi:10.1016/S0140-6736(16)32126-2
Ho GT, Porter RJ, Kalla R. Ulcerative colitis: Recent advances in the
understanding of disease pathogenesis. F1000Research. 2020;9.
doi:10.12688/f1000research.20805.1
Gajendran M, Loganathan P, Catinella AP, Hashash JG. A comprehensive review
and update on Crohn’s disease. Disease-a-Month. 2018;64(2):20-57.
doi:10.1016/j.disamonth.2017.07.001
IBD Medication Guide. http://www.ibdmedicationguide.org/. Accessed March 25,
2021.
Crohn’s Treatment, Crohn’s & Colitis Foundation.
https://www.crohnscolitisfoundation.org/. Accessed March 25, 2021.
Mohebati A, Shaha AR. Anatomy of thyroid and parathyroid glands and
neurovascular relations. Clin Anat. 2012;25(1):19-31. doi:10.1002/ca.21220
Nilsson M, Fagman H. Development of the thyroid gland. Dev.
2017;144(12):2123-2140. doi:10.1242/dev.145615
De Leo S, Lee SY, Braverman LE. Hyperthyroidism. Lancet.
2016;388(10047):906-918. doi:10.1016/S0140-6736(16)00278-6
Chaker L, Bianco AC, Jonklaas J, Peeters RP. Hypothyroidism. Lancet.
2017;390(10101):1550-1562. doi:10.1016/S0140-6736(17)30703-1
Bahn RS, Castro MR. Approach to the Patient with Nontoxic Multinodular Goiter.
J Clin Endocrinol Metab. 2011;96(5):1202-1212. doi:10.1210/jc.2010-2583
Gebremichael G, Demena M, Egata G, Gebremichael B. Prevalence of Goiter and
Associated Factors Among Adolescents in Gazgibla District, Northeast Ethiopia.
Glob Adv Heal Med. 2020;9:216495612092362. doi:10.1177/2164956120923624
Wémeau J louis, Klein M, Sadoul JL, Briet C, Vélayoudom-Céphise FL. Graves’
disease: Introduction, epidemiology, endogenous and environmental pathogenic
factors. Ann Endocrinol (Paris). 2018;79(6):599-607.
doi:10.1016/j.ando.2018.09.002
Ahmed R, Al-Shaikh S, Akhtar M. Hashimoto Thyroiditis. Adv Anat Pathol.
2012;19(3):181-186. doi:10.1097/pap.0b013e3182534868
Aarestrup J, Kitahara CM, Baker JL. Birthweight and risk of thyroid cancer and its
histological types: A large cohort study. Cancer Epidemiol. 2019;62:101564.
doi:10.1016/j.canep.2019.07.003
McGrogan A, Seaman HE, Wright JW, De Vries CS. The incidence of
autoimmune thyroid disease: A systematic review of the literature. Clin
Endocrinol (Oxf). 2008;69(5):687-696. doi:10.1111/j.1365-2265.2008.03338.x
Sajjadi-Jazi SM, Sharifi F, Varmaghani M, Meybodi HA, Farzadfar F, Larijani B.
Epidemiology of hyperthyroidism in Iran: a systematic review and meta-analysis. J
Diabetes Metab Disord. 2018;17(2):345-355. doi:10.1007/s40200-018-0367-1
De Leo S, Lee SY, Braverman LE. Hyperthyroidism. Lancet.

36

68.

69.

70.

71.

72.
73.

74.

75.

76.

77.
78.
79.

80.

81.

82.

83.

2016;388(10047):906-918. doi:10.1016/S0140-6736(16)00278-6
Antonelli A, Ferrari SM, Ragusa F, et al. Graves’ disease: Epidemiology, genetic
and environmental risk factors and viruses. Best Pract Res Clin Endocrinol Metab.
2020;34(1). doi:10.1016/j.beem.2020.101387
Hussain YS, Hookham JC, Allahabadia A, Balasubramanian SP. Epidemiology,
management and outcomes of Graves’ disease—real life data. Endocrine.
2017;56(3):568-578. doi:10.1007/s12020-017-1306-5
Earl R, Crowther CA, Middleton P. Interventions for preventing and treating
hyperthyroidism in pregnancy. In: Cochrane Database of Systematic Reviews.
John Wiley & Sons, Ltd; 2010. doi:10.1002/14651858.cd008633.pub2
Şakı H, Cengiz A, Yürekli Y. Effectiveness of Radioiodine Treatment for Toxic
Nodular Goiter. Malecular Imaging Radionucl Ther. 2015;24(3):100-104.
doi:10.4274/mirt.48378
Leung AM, Braverman LE. Consequences of excess iodine. Nat Rev Endocrinol.
2014;10(3):136-142. doi:10.1038/nrendo.2013.251
Bel Lassen P, Kyrilli A, Lytrivi M, Corvilain B. Graves’ disease, multinodular
goiter and subclinical hyperthyroidism. Ann Endocrinol (Paris). 2019;80(4):240249. doi:10.1016/j.ando.2018.09.004
Ragusa F, Fallahi P, Elia G, et al. Hashimotos’ thyroiditis: Epidemiology,
pathogenesis, clinic and therapy. Best Pract Res Clin Endocrinol Metab.
2019;33(6). doi:10.1016/j.beem.2019.101367
Farahiti J. High risk of thyroid cancer in patients with multinodular goiter. Am
Thyroid Assoc. 2013. https://www.thyroid.org/patient-thyroid-information/ct-forpatients/vol-6-issue-11/vol-6-issue-11-p-6-7/. Accessed March 27, 2021.
Lee HJ, Li CW, Hammerstad SS, Stefan M, Tomer Y. Immunogenetics of
autoimmune thyroid diseases: A comprehensive review. J Autoimmun.
2015;64:82-90. doi:10.1016/j.jaut.2015.07.009
Barker DJP. The Developmental Origins of Adult Disease. J Am Coll Nutr.
2004;23(6 Suppl):588S-595S. doi:10.1080/07315724.2004.10719428
Barker DJP. The fetal and infant origins of adult disease. Br Med J.
1990;301(6761):1111. doi:10.1136/bmj.301.6761.1111
Wang C, Geng H, Liu W, Zhang G. Prenatal, perinatal, and postnatal factors
associated with autism: A meta-analysis. Med (United States). 2017;96(18).
doi:10.1097/MD.0000000000006696
Sciberras E, Mulraney M, Silva D, Coghill D. Prenatal Risk Factors and the
Etiology of ADHD—Review of Existing Evidence. Curr Psychiatry Rep.
2017;19(1):1-8. doi:10.1007/s11920-017-0753-2
Smith CJ, Ryckman KK, Barnabei VM, et al. The impact of birth weight on
cardiovascular disease risk in the Women’s Health Initiative. Nutr Metab
Cardiovasc Dis. 2016;26(3):239-245. doi:10.1016/j.numecd.2015.10.015
Song Y, Huang YT, Song Y, et al. Birthweight, mediating biomarkers and the
development of type 2 diabetes later in life: a prospective study of multi-ethnic
women. Diabetologia. 2015;58(6):1220-1230. doi:10.1007/s00125-014-3479-2
Spracklen CN, Wallace RB, Sealy-Jefferson S, et al. Birth weight and subsequent
risk of cancer. Cancer Epidemiol. 2014;38(5):538-543.
doi:10.1016/j.canep.2014.07.004

37

84.

85.

86.

87.

88.

89.

90.

91.

92.

93.

94.

95.

96.

97.

98.

Spracklen CN, Ryckman KK, Robinson JG, et al. Low birth weight and risk of
later-life physical disability in women. Journals Gerontol - Ser A Biol Sci Med Sci.
2017;72(4):543-547. doi:10.1093/gerona/glw134
Xu XF, Li YJ, Sheng YJ, Liu JL, Tang LF, Chen ZM. Effect of low birth weight
on childhood asthma: A meta-analysis. BMC Pediatr. 2014;14(1).
doi:10.1186/1471-2431-14-275
Wooldridge AL, McMillan M, Kaur M, Giles LC, Marshall HS, Gatford KL.
Relationship between birth weight or fetal growth rate and postnatal allergy: A
systematic review. J Allergy Clin Immunol. 2019;144(6):1703-1713.
doi:10.1016/j.jaci.2019.08.032
Agha G, Hajj H, Rifas-Shiman SL, et al. Birth weight-for-gestational age is
associated with DNA methylation at birth and in childhood. Clin Epigenetics.
2016;8(1):118. doi:10.1186/s13148-016-0285-3
Tobi EW, Heijmans BT, Kremer D, et al. DNA methylation of IGF2, GNASAS,
INSIGF and LEP and being born small for gestational age. Epigenetics.
2011;6(2):171-176. doi:10.4161/epi.6.2.13516
St-Pierre J, Hivert MF, Perron P, et al. IGF2 DNA methylation is a modulator of
newborn’s fetal growth and development. Epigenetics. 2012;7(10):1125-1132.
doi:10.4161/epi.21855
Hoyo C, Fortner K, Murtha AP, et al. Association of cord blood methylation
fractions at imprinted insulin-like growth factor 2 (IGF2), plasma IGF2, and birth
weight. Cancer Causes Control. 2012;23(4):635-645. doi:10.1007/s10552-0129932-y
Ekin A, Gezer C, Taner CE, Solmaz U, Gezer NS, Ozeren M. Prognostic value of
fetal thymus size in intrauterine growth restriction. J Ultrasound Med.
2016;35(3):511-517. doi:10.7863/ultra.15.05039
Diemert A, Hartwig I, Pagenkemper M, et al. Fetal thymus size in human
pregnancies reveals inverse association with regulatory T cell frequencies in cord
blood. J Reprod Immunol. 2016;113:76-82. doi:10.1016/j.jri.2015.12.002
Bao S, Kanno E, Maruyama R. Blunted autonomic responses and low-grade
inflammation in Mongolian adults born at low birth weight. Tohoku J Exp Med.
2016;240(2):171-179. doi:10.1620/tjem.240.171
Anderson G, Cummings S, Freedman LS, et al. Design of the Women’s Health
Initiative clinical trial and observational study. Control Clin Trials. 1998;19(1):61109. doi:10.1016/S0197-2456(97)00078-0
Prentice RL, Anderson GL. The women’s health initiative: Lessons learned. In:
Annual Review of Public Health. Vol 29. ; 2008:131-150.
doi:10.1146/annurev.publhealth.29.020907.090947
Mandl LA, Costenbader KH, Simard JF, Karlson EW. Is birthweight associated
with risk of rheumatoid arthritis? data from a large cohort Study. Ann Rheum Dis.
2009;68(4):514-518. doi:10.1136/ard.2007.080937
Svendsen AJ, Kyvik KO, Houen G, et al. Newborn infant characteristics and risk
of future rheumatoid arthritis: A twin-control study. Rheumatol Int.
2014;34(4):523-528. doi:10.1007/s00296-013-2886-x
Carlens C, Jacobsson L, Brandt L, Cnattingius S, Stephansson O, Askling J.
Perinatal characteristics, early life infections and later risk of rheumatoid arthritis

38

99.

100.
101.

102.

103.

104.
105.

106.

107.

108.

109.

110.

111.

112.

113.

and juvenile idiopathic arthritis. Ann Rheum Dis. 2009;68(7):1159-1164.
doi:10.1136/ard.2008.089342
Parks CG, D’Aloisio AA, DeRoo LA, et al. Childhood socioeconomic factors and
perinatal characteristics influence development of rheumatoid arthritis in
adulthood. Ann Rheum Dis. 2013;72(3):350-356. doi:10.1136/annrheumdis-2011201083
H Jacobsson LT, Jacobsson ME, Askling J, Knowler WC. RESEARCH
POINTERS. https://about.jstor.org/terms. Accessed October 6, 2020.
Coleman LA, Naleway AL, Davis ME, Greenlee RT, Wilson D, McCarty DJ.
Birth weight and systemic lupus erythematosus. Lupus. 2005;14(7):526-528.
doi:10.1191/0961203305lu2152oa
Arkema E V., Simard JF. Perinatal risk factors for future SLE: A population-based
nested case-control study. Lupus. 2015;24(8):869-874.
doi:10.1177/0961203315570160
Parks CG, D’Aloisio AA, Sandler DP. Early life factors associated with adultonset systemic lupus erythematosus in women. Front Immunol. 2016;7(MAR):31.
doi:10.3389/fimmu.2016.00103
Simard JF, Karlson EW, Costenbader KH, et al. Perinatal factors and adult-onset
lupus. Arthritis Care Res. 2008;59(8):1155-1161. doi:10.1002/art.23930
Ramagopalan S V., Valdar W, Dyment DA, et al. No effect of preterm birth on the
risk of multiple sclerosis: A population based study. BMC Neurol. 2008;8.
doi:10.1186/1471-2377-8-30
Gardener H, Munger KL, Chitnis T, Michels KB, Spiegelman D, Ascherio A.
Prenatal and perinatal factors and risk of multiple sclerosis. Epidemiology.
2009;20(4):611-618. doi:10.1097/EDE.0b013e31819ed4b9
Luetic GG, Menichini ML, Deri N, et al. High birth weight and risk of multiple
sclerosis: A multicentre study in Argentina. Mult Scler Relat Disord.
2021;47:102628. doi:10.1016/j.msard.2020.102628
Khalili H, Ananthakrishnan AN, Higuchi LM, Richter JM, Fuchs CS, Chan AT.
Early life factors and risk of inflammatory bowel disease in adulthood. Inflamm
Bowel Dis. 2013;19(3):542-547. doi:10.1097/MIB.0b013e31828132f8
Mendall M, Jensen CB, Ängquist LH, Baker JL, Jess T. Childhood growth and risk
of inflammatory bowel disease: a population-based study of 317,030 children.
Scand J Gastroenterol. 2019;54(7):863-868. doi:10.1080/00365521.2019.1635201
Cardwell CR, Stene LC, Joner G, et al. Birthweight and the risk of childhood-onset
type 1 diabetes: a meta-analysis of observational studies using individual patient
data. Diabetologia. 2010;53(4):641-651. doi:10.1007/s00125-009-1648-5
Goldacre RR. Associations between birthweight, gestational age at birth and
subsequent type 1 diabetes in children under 12: a retrospective cohort study in
England, 1998–2012. Diabetologia. 2018;61(3):616-625. doi:10.1007/s00125-0174493-y
Lindell N, Bladh M, Carlsson A, Josefsson A, Aakesson K, Samuelsson U. Size
for gestational age affects the risk for type 1 diabetes in children and adolescents: a
Swedish national case–control study. Diabetologia. February 2021:1-8.
doi:10.1007/s00125-021-05381-y
Waernbaum I, Dahlquist G, Lind T. Perinatal risk factors for type 1 diabetes

39

114.

115.

116.

117.

118.

119.

120.

revisited: a population-based register study. Diabetologia. 2019;62(7):1173-1184.
doi:10.1007/s00125-019-4874-5
Brix TH, Kyvik KO, Hegedüs L. Low birth weight is not associated with clinically
overt thyroid disease: a population based twin case-control study. Clin Endocrinol
(Oxf). 2000;53(2):171-176. doi:10.1046/j.1365-2265.2000.01025.x
Rumball CWH, Harding JE, Oliver MH, Bloomfield FH. Effects of twin
pregnancy and periconceptional undernutrition on maternal metabolism, fetal
growth and glucose-insulin axis function in ovine pregnancy. J Physiol.
2008;586(5):1399-1411. doi:10.1113/jphysiol.2007.144071
Kitahara CM, Slettebø Daltveit D, Ekbom A, et al. Maternal health, in-utero, and
perinatal exposures and risk of thyroid cancer in offspring: a Nordic populationbased nested case-control study. Lancet Diabetes Endocrinol. 2021;9(2):94-105.
doi:10.1016/S2213-8587(20)30399-5
Deziel NC, Zhang Y, Wang R, et al. Birth Characteristics and Risk of Pediatric
Thyroid Cancer: A Population-Based Record-Linkage Study in California.
Thyroid. October 2020. doi:10.1089/thy.2020.0217
Wodskou PM, Hundrup YA, Obel EB, Jørgensen T. Validity of self-reported
birthweight among middle-aged and elderly women in the Danish Nurse Cohort
Study. Acta Obstet Gynecol Scand. 2010;89(9):1134-1139.
doi:10.3109/00016349.2010.500370
Jaworowicz DJ, Nie J, Bonner MR, et al. Agreement between self-reported birth
weight and birth certificate weights. J Dev Orig Health Dis. 2010;1(2):106-113.
doi:10.1017/S2040174410000012
Talebi S, Ghaedi E, Sadeghi E, et al. Trace Element Status and Hypothyroidism: A
Systematic Review and Meta-analysis. Biol Trace Elem Res. 2019.
doi:10.1007/s12011-019-01963-5

40

